Summary of Key Points Core Viewpoint The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., has decided to change the use of part of the raised funds from its convertible bond issuance to better align with its current development needs and strategic planning. Group 1: Fundraising Overview - The company issued 5 million convertible bonds with a total fundraising amount of 500 million RMB, netting 491.44 million RMB after deducting fees [1][2] - The original project for the raised funds was the industrialization of lightweight pharmaceutical molded glass bottles, with a total investment of 641.87 million RMB [2][4] - As of August 10, 2025, 126.05 million RMB of the raised funds had been utilized, leaving an unused amount [2][4] Group 2: Change in Fund Usage - The company plans to reallocate 154 million RMB from the original project to two new projects: acquiring a 30% stake in Chuangyang Co. and the second phase of the high-end pharmaceutical packaging project [2][5] - The new projects include an investment of 84 million RMB for the acquisition and 70 million RMB for the high-end packaging project [2][5] Group 3: Rationale for Change - The original project faced delays due to late delivery of construction facilities and lengthy customer certification processes, leading to a reduced funding requirement [4][5] - The company received a government subsidy of 89.58 million RMB for the original project, further decreasing the need for raised funds [4][5] Group 4: New Investment Projects - The acquisition of a 30% stake in Chuangyang Co. aims to enhance the company's product offerings and market share in pharmaceutical packaging [5][8] - The second phase of the high-end packaging project focuses on RTU (Ready-to-Use) packaging and pre-filled syringes, with a total investment of 383.37 million RMB [9][10] - The project is expected to have a payback period of 6.82 years and an internal rate of return of 16.37% [9] Group 5: Strategic Importance - The new projects align with the growing demand for high-quality pharmaceutical packaging driven by trends in the pharmaceutical industry [10][11] - The company aims to transition from a traditional pharmaceutical glass manufacturer to a diversified high-end packaging solution provider [10][12] - The strategic shift is supported by national policies promoting the development of the pharmaceutical packaging industry [13][14] Group 6: Approval Process - The board of directors and the supervisory board have approved the change in fund usage, ensuring compliance with relevant regulations [16][17] - The independent directors also confirmed that the decision aligns with the company's interests and does not harm shareholder value [17][18]

山东力诺医药包装股份有限公司 第四届董事会独立董事 2025 年第五次专门会议审核意见 根据《中华人民共和国公司法》 《深圳证券交易所创业板股票上市规则》 《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律、法规和规范性文件以及《公司章程》的有关规定，山东力诺医药包装股份有 限公司（以下简称"公司"）独立董事召开了第四届董事会独立董事 2025 年第五 次专门会议，审议通过了《关于公司<2025 年半年度募集资金存放与使用情况的 专项报告>的议案》《关于变更部分募集资金用途的议案》《关于拟对外投资购买 股权的议案》 《关于购买董监高责任险的议案》 经核查，我们认为：本次交易是基于公司业务发展需要，为实现公司长远发 展战略规划而做出的整体安排，有利于整合公司与苏州创扬新材料科技股份有限 公司的资源和优势，实现资源共享、共同发展。本次交易风险可控，投资资金来 源于公司募集资金，不会影响公司生产经营活动和现金流的正常运转，不会对公 司未来财务及经营状况产生重大影响，不存在损害上市公司及股东利益的情形。 我们一致同意本次对外投资购买股权事项。 四、关于购买董监高责任险的审核意见 经核 ...

Summary of Key Points Core Viewpoint - The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., plans to establish a joint venture with its controlling shareholder, Linuo Group, to utilize idle land resources and leverage Linuo Group's expertise in park construction and management [1][2]. Group 1: Overview of Related Transactions - The joint venture, named Linuo Innovation Technology (Shanghe) Co., Ltd., will be established with Linuo Group holding 51% and the company holding 49% through land contributions valued at approximately RMB 45.41 million [1][4]. - This transaction is classified as a related party transaction due to Linuo Group being the controlling shareholder of the company [2]. - The board of directors approved the investment proposal on August 19, 2025, with independent directors also consenting, thus not requiring shareholder approval [2][8]. Group 2: Financial and Governance Structure - The company will contribute land valued at RMB 45.41 million, while Linuo Group will provide cash for its share [5]. - The governance structure of the joint venture will involve a board elected by shareholders, with the chairman also serving as the general manager [5]. Group 3: Purpose and Impact of the Joint Venture - The primary goal of the joint venture is to revitalize idle land resources and develop a "Science and Technology Innovation Center" [6]. - The collaboration is expected to enhance resource integration and expedite land development, aligning with the company's future growth needs [7]. Group 4: Compliance and Approval Process - The related party transaction has been reviewed and approved by the board and independent directors, adhering to relevant regulations and company policies [8]. - The total amount of related transactions with Linuo Group and its subsidiaries for the year to date is RMB 2.5151 million, excluding this transaction [7].

Core Viewpoint - The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., is changing the use of part of the raised funds from its convertible bond issuance to better align with its strategic development needs and improve fund utilization efficiency [2][19]. Summary by Sections Fundraising Overview - The company issued 5 million convertible bonds with a net fundraising amount of RMB 491.4447 million, after deducting underwriting fees [2][3]. - As of August 10, 2025, a total of RMB 126.0511 million has been invested from the raised funds, with the remaining amount stored in dedicated bank accounts [3][5]. Change in Fund Usage - The company plans to change the use of RMB 154 million from the "Lightweight Pharmaceutical Glass Bottle (Class I) Industrialization Project" to invest in two new projects: acquiring 30% equity in Suzhou Chuangyang New Materials Technology Co., Ltd. and the second phase of the high-end pharmaceutical packaging project [3][4]. - The new projects include an investment of RMB 84 million for the equity acquisition and RMB 154 million for the high-end packaging project [3][6]. Reasons for Change - The original project faced delays due to late delivery of construction facilities and longer customer certification cycles, leading to a reduced need for the originally planned funds [5][6]. - The company received a government subsidy of RMB 89.58 million, which decreased the funding requirement for the original project [5][6]. New Investment Projects - The acquisition of 30% equity in Suzhou Chuangyang New Materials is aimed at enhancing the company's product offerings and market share in pharmaceutical packaging [6][10]. - The second phase of the high-end pharmaceutical packaging project focuses on the production of Ready-to-Use (RTU) packaging and pre-filled syringes, with a total investment of RMB 383.3725 million, of which RMB 70 million will come from the raised funds [10][11]. Impact of Changes - The changes in fund usage are expected to enhance the company's operational efficiency and long-term benefits without adversely affecting its existing business or financial status [19][20]. - The company will implement strict internal and external supervision of the fund usage to ensure compliance with relevant regulations [20][21].

Core Viewpoint - Shandong Linuo Pharmaceutical Packaging Co., Ltd. reported a revenue of 499 million yuan and a net profit of 40.97 million yuan for the first half of 2025, while facing external pressures such as weak terminal demand and declining product prices. The company aims to stabilize operations, improve efficiency, and pursue expansion through both its core business and external acquisitions [1][5]. Group 1: Business Performance - The company achieved a total asset value of 2.537 billion yuan by the end of the reporting period [1]. - The production capacity of borosilicate pharmaceutical glass has been further enhanced, with the first kiln of the lightweight molded glass bottle project having been put into operation in February 2025 [1]. - The increase in production capacity is expected to meet the growing demand from downstream customers and expand the company's market share in the pharmaceutical packaging sector [1]. Group 2: Brand Development and Transformation - The company is accelerating its transformation towards self-owned brands, having established an e-commerce company in Hangzhou to promote its domestic brand "LEBOLEBO" and international brand "brohouse" [3]. - Since 2025, the company has been enhancing its internal design capabilities to launch fashionable glass products that cater to younger consumers, transitioning from an OEM to an ODM model [3]. Group 3: External Expansion and Strategic Investments - The company plans to invest in high-quality enterprises in the pharmaceutical packaging sector as part of its external development strategy for 2025, aiming to broaden its product range and provide one-stop procurement for pharmaceutical clients [3]. - The company has conducted assessments in regions such as Saudi Arabia, Brazil, and Southeast Asia, and signed a cooperation investment agreement with SANTISA in March 2025 [3]. Group 4: Joint Ventures and Acquisitions - The company announced a joint investment of 92.65 million yuan with Linuo Group to establish Linuo Innovation Technology (Shanghe) Co., Ltd., focusing on revitalizing idle land resources and creating a high-end pharmaceutical packaging industry platform [5][7]. - The company plans to acquire a 30% stake in Suzhou Chuangyang New Materials Technology Co., Ltd. for 84 million yuan, which will enhance its service capabilities by integrating plastic packaging materials with its existing glass offerings [7]. Group 5: Financial Health - The company reported a net cash outflow of 96.05 million yuan from operating activities due to increased raw material inventory and slower sales collection [8]. - The company maintains a cash reserve of 537 million yuan, which, along with unused fundraising and bank credit, is sufficient to cover convertible bond repayments, project construction, and acquisition funding needs [8]. - The debt-to-asset ratio stands at 37.1%, indicating a relatively low level compared to the industry, allowing for ample leverage for future expansion [9].

作为国民经济的"稳定器""压舱石"，央企控股上市公司长期以来发挥着引领者、破局者的作用。其中， 科技型央企更是在维护国家重大事项安全、推动经济纵深发展等方面扮演着重要的角色。 近日，"我是股东——走进央企控股上市公司专项投关活动"在上海证券交易所中部基地（武汉）举行。 来自长飞光纤、烽火通信、华强科技等3家科技型上市公司的高管，围绕"价值与投资——书写强国建设 新答卷"主题，与投资者分享了企业科技创新及发展战略的新进展、新规划。 新一轮国企改革强调，要发挥好国企特别是央企的引领作用，在科技自立自强上展现新作为。与会高管 一致认为，企业作为创新主体，在强国建设中要有"主人翁"精神，以产学研结合、机制优化等激发企业 科技创新活力，持续为强国建设助力。 推进科技自立自强成果丰硕 本次活动得到了中国证券投资基金业协会的大力支持，中基协组织不少基金公司代表与上市公司进行了 互动交流。专业的机构投资者积极参与上市公司治理，也为助力上市公司高质量发展增添了新动力。 作为科技创新的"排头兵"，央企持续加大研发投入，攻克并掌握了众多核心技术，为关键产业领域的强 链补链延链注入强劲动力。 "经过35年的发展，以长飞光纤为代表的一 ...

Group 1 - The core viewpoint of the news is the establishment of a joint innovation laboratory between Tuokene Technology and Geely Automobile Research Institute to address the bottlenecks in the COC industry and promote the development of automotive optical materials [1][2] - Tuokene Technology has achieved continuous stable production of COC with a newly built production line of 3,000 tons per year, overcoming challenges in the entire supply chain from raw material supply to processing [2] - The collaboration aims to fill the technological gap in high-end optical materials for vehicles, which is crucial for the "visual system" in smart cars, impacting user experience and driving safety [2][3] Group 2 - Tuokene Technology's products, such as "TAMT," have achieved domestic substitution in various fields including optical lenses, biomedical applications, and smart cockpits [2] - The partnership with Shanghai Haishun New Material Co., Ltd. in the life sciences sector highlights the importance of technological breakthroughs and industry chain collaboration [2] - The use of COC in pharmaceutical packaging addresses issues such as low barrier material usage and poor stability, ensuring the safety and stability of drug packaging [3]

力诺药包（301188）(301188.SZ)公告，公司股东复星惟实及其一致行动人复星惟盈拟减持公司股份不 超697.87万股，占公司总股本比例为3.0000%;公司原董事、股东徐广成拟减持公司股份不超142.86万 股，占公司总股本比例为0.6141%。 ...

Group 1 - The core revenue composition of Dongfeng Group for the year 2024 is as follows: pharmaceutical packaging accounts for 44.36%, membrane new materials for 27.58%, paper products for 10.08%, others for 7.4%, and cigarette labels for 6.2% [1] Group 2 - As of August 1, 2025, Dongfeng Group announced that it has repurchased approximately 7.68 million shares, representing about 0.41% of the company's total share capital [3] - The highest price for the repurchased shares was RMB 3.93 per share, while the lowest price was RMB 3.03 per share, with a total expenditure of approximately RMB 26.64 million [3]

Group 1 - The aviation and aerospace industry in Zhenjiang Economic Development Zone provides 10% of composite material structural components for domestic large aircraft, attracting talent from local universities [1] - The collaboration between Zhenjiang Economic Development Zone and Nanjing University of Technology has facilitated job opportunities for graduates, with 291 graduates hired in recent years, including 59 master's degree holders [2] - The government offers various subsidies, including 800 yuan monthly rent subsidy, 1000 yuan living subsidy, and up to 150,000 yuan housing subsidy, enhancing the income of returning graduates [2] Group 2 - The biopharmaceutical and health industry in Zhenjiang is also attracting talent, with companies like Greiner Bio-One establishing new production lines for pharmaceutical packaging, indicating a strong market potential [3] - Zhenjiang Economic Development Zone has issued 18.05 million yuan in subsidies to 9,317 graduates this year, a 27.8% increase year-on-year, addressing urgent issues faced by talent [3] - The government is enhancing the sense of belonging for talent by solving housing and medical service issues for employees in key enterprises [3] Group 3 - Zhenjiang Economic Development Zone is building a virtuous ecosystem of dual empowerment between talent and industry through deepening collaboration with universities and optimizing policy support [4] - The zone aims to continue improving employment policies and service platforms, promoting the integration of education, talent, and industry chains for sustainable high-quality development [4]